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Purpose 
Decision aids (DA) are evidence-based tools that support shared decision-making (SDM) 
implementation in practice; this study aimed to identify existing osteoporosis DAs and assess their 
quality and efficacy; and to gain feedback from a patient advisory group on findings and implications 
for further research.  
Methods 
We searched multiple bibliographic databases to identify research studies from 2000 to 2019 and 
undertook an environmental scan (search conducted February 2019, repeated in March 2020). A 
pair of reviewers, working independently selected studies for inclusion, extracted data, evaluated 
each trial’s risk of bias, and conducted DA quality assessment using the International Patient 
Decision Aid Standards (IPDAS). Public contributors (patients and caregivers with experience of 
osteoporosis and fragility fractures) participated in discussion groups to review a sample of DAs, 
express preferences for a new DA and discuss plans for development of a new DA. 
Results 
We identified 6 studies, with high or unclear risk of bias. Across included studies, use of an 
osteoporosis DA was reported to result in reduced decisional conflict compared with baseline, 
increased SDM and increased accuracy of patients’ perceived fracture risk compared with controls. 
Eleven DAs were identified, of which none met the full set of IPDAS criteria for certification for 
minimization of bias. Public contributors expressed preferences for encounter DAs that are 
individualized to patients’ own needs and risk.  
Conclusions  
Existing DAs for informing patient decisions about osteoporosis treatment fail to comprehensively 
meet international quality standards and patient needs, underpinning the need for new DA 
development.  
 
Mini Abstract 
Using a systematic review and environmental scan we identified 11 decision aids to inform patient 
decisions about osteoporosis treatment and 6 studies evaluating their effectiveness. Use of decision 
aids increased accuracy of risk perception and shared decision-making but the decision aids 
themselves fail to meet quality standards or patient needs.  
 
  
Introduction 
Despite the significant mortality and morbidity associated with fragility fractures, and the benefits of 
treatment, 85% of patients in need of fracture prevention treatment, such as bisphosphonates, do 
not receive it [1]. Furthermore, the number of women starting fracture prevention treatment is 
declining, despite the ageing population in need of treatment increasing [2]. The reasons for this 
decline are complex; however, the problem is not solely related to rates of identification of patients 
at risk: 25% of patients who are recommended bisphosphonates actively decide against starting 
treatment [3].  In those who do decide to start treatment, long term persistence is known to be poor 
[4]. Reasons for treatment non-initiation and non-persistence include skepticism over benefits and 
safety, lack of understanding of the consequences of non-treatment and/or fracture risk 
assessments and perceived or experienced side effects [5, 6]. The poor uptake of osteoporosis 
treatment globally has been described as the ‘osteoporosis crisis’, and it has been suggested that a 
major contributing factor to this situation is the failure of clinicians to adequately and accurately 
communicate risks such as the risk of poor disease outcome (prognosis) and the harms and benefits 
relating to treatment options [7]. Furthermore, patients have identified improving access to 
information from health professionals as the most important area for research in osteoporosis [8].  
Decision aids (DAs) are tools that support the implementation of shared decision-making (SDM) in 
practice. SDM is an approach in which patients and clinicians work together to develop a treatment 
plan that responds well to the patient’s situation.  DAs may provide numerical estimates of 
risk/benefit and are a well-recognized mechanism to improve risk communication and support 
informed patient decision-making [9, 10]. Across a range of conditions, DAs have been 
demonstrated to increase patient knowledge, reduce decisional conflict, increase patient 
participation in decision-making, improve the accuracy of risk perception, and improve uptake of 
preventative treatments [9]. The UK National Institute for Health and Care Excellence (NICE) 
guidance recommends DAs to support SDM, if ‘high quality’ aids are available [11], and International 
Standards for Patient Decision Aids (IPDAS) readily facilitate such quality assessment [12]. 
SDM supported by use of DAs has the potential to improve the likelihood of each patient receiving 
and taking fracture prevention medication given their risk, informed preferences, and personal 
circumstances. In this way, implementing SDM can account for how different patients in different 
situations assign different value and priority to reducing their fracture risk, choosing from strategies 
such as the use of particular medications. To our knowledge, the impact of DAs to promote SDM in 
the care of patients with osteoporosis considering treatment has not been systematically 
summarized.  
Our study had two aims. First, we conducted a systematic review to identify and summarize research 
studies which had assessed the efficacy of existing osteoporosis DAs. Second, we aimed to identify 
existing osteoporosis DAs and assess their quality. We assumed that not all existing DAs had been 
evaluated in scientific peer reviewed publications, so we supplemented the systematic review with a 
broader range of search methods to identify existing DAs using an environmental scan method. 
Additionally, we sought feedback from an advisory group of public contributors and discussed 
preferences for the design of a new DA, in line with international guidance on DA development [13].  
 
Methods 
An overview of the methods is shown in Figure 1.   
Fig 1. Overview of study methods 
Protocol and Registration 
The protocol for the systematic review was previously published and registered in the International 
Prospective Register of Systematic Reviews (PROSPERO registration number CRD42019126787) [14]. 
This report adheres to the Preferred Reporting Items for Systematic Review and Meta-analysis 
(PRISMA) standards.   
Eligibility criteria 
We included DAs, and efficacy studies about DAs, relevant to people facing a decision about 
osteoporosis treatment or fracture prevention strategies in patients with osteoporosis. Identified 
DAs had to be sufficiently available to perform quality assessments i.e. the DA was either fully 
available or we had sufficient information on screenshots in papers included in the systematic 
review to be able to judge quality. We excluded DAs intended to help decide whether or not to 
perform a diagnostic test, those available in a language different than English, those intended only 
for education rather than clinical decision support, and those designed only for clinicians. For 
efficacy assessment, eligible studies were randomized or non-randomized trials that evaluated DAs 
impact on SDM outcomes (e.g. decisional conflict, knowledge), patient outcomes such as quality of 
life or anxiety and clinical outcomes such as adherence.  
Information Sources and Search Strategy 
For the systematic review, a comprehensive search of several databases was conducted from 2000 
to 5th February 2019 (and subsequently repeated up to 24th March 2020), limited to English. The 
databases included Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed 
Citations, and Daily, Ovid EMBASE, Ovid PsycINFO, Ovid Cochrane Central Register of Controlled 
Trials, Ovid Cochrane Database of Systematic Reviews, Web of Science, and Scopus.  The search 
strategy was designed and conducted by an experienced librarian with input from one author (VTR). 
Controlled vocabulary supplemented with keywords was used to search for osteoporosis DAs. The 
search strategy is available in Supplementary Table 1. 
The environmental scan was informed by the methodology employed by previous environmental 
scans about DAs [15, 16]. Three additional searches were conducted: a search of an existing DA 
database, social media and Google. Initially, in December 2017, a search of an international DA 
database (the Ottawa DA A-Z inventory) was conducted using the terms ‘osteoporosis’ and 
‘bisphosphonate’. In October 2019, and updated in March 2020, the search of the Ottawa database 
was repeated and we searched social media, namely Facebook, Twitter and Instagram using the 
terms ‘osteoporosis’, ‘bone fracture’, ‘shared decision-making’, and ‘decision aid’. Terms were 
entered as words and ‘hashtags’.  In addition, a Google search was conducted, using the terms 
‘osteoporosis’ and ‘decision aid’ or ‘decision tool’ with the first 100 hits being screened (an approach 
used in a previous environmental scan [15].)  
Study and DA Selection 
Two reviewers independently screened all titles and abstracts. Full texts were retrieved and 
independently screened by two reviewers with acceptable reproducibility (weighted overall kappa = 
0.69). Disagreements during title, abstract or full text screening were resolved by a third reviewer 
(JPB).   
DAs were identified from the systematic review and social media search by VTR and MUS, and from 
the Ottawa database and google by AH and ZP. Two authors (VTR and ZP) agreed identified DAs met 
inclusion criteria.   
Data Extraction and Quality Assessment 
Data from eligible research studies was extracted in duplicate by 4 reviewers (VTR, MUS, GFT, and 
LM) on: study design, setting, target population, and characteristics of participants (e.g. age, sex, 
baseline risk of fracture). Risk of bias of included studies was assessed by 3 reviewers (VTR, MUS and 
GFT) using the 7-item Cochrane Collaboration's risk assessment tool.  
Of the DAs identified in both the systematic review and environmental scan, data was extracted by 
two authors (AH and ZP) on: the availability (e.g. online or paper) and intended use, the target 
population the tool was designed for, the nature of the options, risks and benefits explained and the 
method of displaying these risks and benefits. Two authors (VTR and AH or LB) reviewed the 
satisfaction of International Patient Decision Aids Standards (IPDAS) criteria for each included DA 
independently, using a binary yes/no scale, and resolved any disagreements by discussion with a 
third author (ZP). The 44-item IPDAS v4.0 checklist criteria were used, excluding the 9 items relating 
to diagnostic tests [12]. This checklist includes dimensions relating to the information provided, 
probabilities presented, values elicitation, guiding the patient through making a decision, 
development of the DA, the evidence underpinning the DA, disclosures, use of plain language and 
evaluation of the DA [12]. Six of the 44 items, described as ‘qualifying’ are considered essential for a 
DA to meet the classification of a DA with evidence of a further six ‘certification’ criteria required to 
reach certification standards [12]. The full list of criteria (35 items used), is available in 
Supplementary Table 2.  
Synthesis 
In the systematic review, we considered SDM outcomes such as decisional conflict, knowledge, 
patient participation in decision-making, preference in treatment decisions, risk expectations and 
perceptions, etc. Patient important and surrogate outcomes were also considered. We planned to 
synthesize outcome data quantitatively using random effects model. However, we reported data 
narratively due to heterogeneity in reporting across the 6 studies.  
Patient and public involvement: advisory group  
Public contributors were invited to attend an advisory group in December 2017 in which the DAs 
identified in the first search were reviewed. Discussion groups differ from focus groups. In focus 
groups with patients, patients are participants in qualitative research, designed to answer a research 
question.  In advisory discussion groups, public contributors inform and advise the research process, 
e.g. project decision making and study design, in partnership with researchers. This emphasizes co-
learning, multi-way communication and collaboration between the participants and facilitators [17]. 
The GRIPP2 guided the reporting of patient and public involvement (PPI) [18]. 
Public contributors in our osteoporosis Research User Group consist of men and women with 
experience of osteoporosis and/or fragility fractures and people with experience of caring for people 
with osteoporosis. Public contributors from the osteoporosis Research User Group were invited to 
attend, and asked to comment on general impressions towards the DAs appearance, the suitability 
of the DA for use in a clinical consultation and whether, or not, the information regarding fracture 
risk felt tailored or relevant to their individual characteristics. Additionally, they were asked their 
requirements and preferences for the development of a new DA. The advisory discussion group was 
facilitated by ZP and SC. Discussion notes were written with the intention of drawing on participants’ 
expertise in order to inform decision-making in relation to future research [17].  
 
Results 
Systematic review: summary of included studies 
We identified 2199 records which resulted in the inclusion of 15 studies [19–33] that referred to one 
or more eligible DAs (Figure 2). Six of the 15 studies evaluated DAs’ impact on 8 outcomes and were 
included for data extraction; the other studies were used as complementary when assessing decision 
aid’s quality using IPDAS in the environmental scan.  
Fig 2. PRISMA Flow diagram 
Six studies reporting impact on SDM and other relevant outcomes contributed 507 participants 
(Table 1) [19, 24, 26, 28, 31, 33]. Five were randomized controlled trials (RCTs) [24, 26, 28, 31, 33], 
the other was a pseudo-experimental before and after study [19]. Two RCTs evaluated the impact of 
the Osteoporosis Choice DA in the clinical encounter [28, 31], one RCT evaluated a multimedia tool 
and printed booklet for use in outpatients (but designed to be read alone) [24], and the remaining 
three evaluated DAs which are no longer freely available (the paper Healthy Bones DA used both 
before, and in the encounter [33], with the remaining two evaluating versions of the ‘Making 
Choices’ DA used before the encounter [19, 26]). Of note, the control arm in all but one study 
encompassed usual care or an existing educational booklet; however, in the study evaluating the 
multimedia tool, the control arm intervention received a booklet which was noted to contain similar 
information to the multimedia tool, and was also given to participants in the intervention arm [24]. 
Participants enrolled in these studies were all postmenopausal women with mean ages ranging 50-
77 years old. Five studies specified educational status: in four studies, participants were 
predominantly educated, the majority completed high school or a greater degree [19, 28, 31, 33]. 
Only one study reported health literacy measured at baseline and reported 82% of the sample had 
acceptable health literacy [24]. Treatment status was variable; one study included only participants 
in treatment for osteoporosis [26], two studies included only participants with untreated 
osteoporosis [28, 31], and three studies included participants with osteoporosis irrespectively of 
their treatment status [19, 24, 33].  
Risk of bias assessment 
Among all studies, four trials received an “unclear” risk of bias using the Cochrane tool [24, 26, 28, 
33], and two trials study received a “high” risk of bias (Figure 3) [19, 31]. Overall,  absence or 
inadequate reporting of allocation concealment but especially blinding of participants, personnel 
and outcome assessors were important sources of potential bias among these studies.  
Fig 3. Risk of bias of effectiveness studies 
Effectiveness of decision aids. 
The outcomes evaluated related to decisional quality (decisional conflict, realistic expectations, 
knowledge) decisional process (involvement in decision-making, preparation for SDM and SDM), 
quality of life and adherence (Table 2). 
Four studies compared decisional conflict immediately after the encounter in intervention arm and 
controls, all studies found lower decisional conflict scores in the DA arms [24, 28, 31, 33], and two, 
evaluating the Healthy Bones DA and multimedia tool [24, 33] reported a statistically significant 
difference. Two studies compared decisional conflict before and after using the Making Choices DA 
and both reported statistically significant lower decisional conflict scores post-DA compared to 
baseline [19, 26]. The only trial to measure health literacy found that of the participants with limited 
health literacy, those in the control arm (receiving booklet only) had a greater (significant) reduction 
in decisional conflict at 6 months than those in the arm receiving a multimedia tool [24]. Both trials 
with Osteoporosis Choice found a significant difference in percentage of patients that identified 
correctly their risk category post-intervention  [28, 31]. The results were consistent with the Making 
Choices before and after study [19]. The two Osteoporosis Choice RCTs [28, 31] and the Making 
Choices before and after study [19] measured knowledge immediately post-intervention using non-
validated and validated questionnaires. Both trials found a significant difference when measuring 
knowledge specific to the DA, but no difference in generic knowledge [28, 31]. The results were 
consistent with the before and after study [19]. Furthermore, in the RCT of the multimedia tool 
compared with booklet, osteoporosis knowledge improved from baseline to all time points in both 
trial arms [24]. 
Two randomized trials measured involvement in decision-making using the OPTION score [28, 31]. 
Both trials found a significant higher involvement when using the Osteoporosis Choice DA. 
One randomized trial measured quality of life at 6 months using the EURO QoL5d Health 
Thermometer tool [31]; with no difference in quality of life observed between intervention and 
controls.  
Three randomized trials measured adherence at >4 months, using different measures [26, 28, 31]. 
Overall, no study found a difference in adherence when using a DA, although one Osteoporosis 
Choice study [31] found, more patients initiated treatment (filled the prescription) in the 
intervention arm compared with controls (80% compared with 43%, p=0.07). 
Environmental Scan: summary of included decision aids 
Eleven DAs were identified for evaluation (Supplementary Figure 1), of which 5 were identified in 
the systematic review with a further 6 identified in searches of Ottawa A to Z inventory and social 
media. The google search did not add any new DAs.  
The characteristics of the 11 DAs identified are described in Supplementary Table 3. Two of the DAs 
identified are no longer available (Healthy Bones and Making Choices) but sufficient information was 
available within the related research studies to rate using the IPDAS criteria [19, 20, 33]. Of the 9 
currently available DAs, three are interactive dynamic websites, two of which are designed for use in 
the encounter; individual risk factors are entered in order to calculate fracture risk (Osteoporosis 
Choice and HealthDecision). One of the interactive DAs not meant for the encounter includes a 
values clarification exercise (Healthwise). Five DAs are printable PDF files. Four of these have 
sections to complete about fracture risk (AACE/ACE) or values, decisions and knowledge (three 
Cochrane tools). Finally, one DA comprised a multimedia tool and associated printed booklet; the 
tool comprised learning modules with information on osteoporosis, its risk factors, prevention, and 
management, using a set of dramatized episodes recorded on video and viewed on a computer. 
All DAs discussed treatment options relating to bisphosphonates, with AACE/ACE, Healthy Bones, 
Making Choices and the multimedia tool including information about other treatment options 
(including Teriparatide, denosumab, raloxifene, HRT and Calcitonin). Two DAs made reference to 
falls prevention (Osteoporosis Choice and multimedia tool). The Cochrane, Healthwise and Making 
Choices DA are explicitly for postmenopausal women only. Six DAs used Cates plots to demonstrate 
fracture risk with and without treatment (Cochrane tools, Osteoporosis Choice, HealthDecision and 
NICE). The remainder used either textual descriptions (Healthwise), descriptions of frequencies 
(Making Choices) or other visual methods e.g. ticks (AACE/ACE, Healthy Bones, multimedia tool) to 
show benefits of treatment. Side effects were mostly described using frequencies with the 
HealthDecision and Cochrane tools expressing side effects visually in a Cates plot.  
Quality of Decision Aids 
Full IPDAS results for each DA are shown in Figure 4. The Making Choices DA was rated as meeting 
the most number of criteria (28/35, 80%), with the AACE/ACE tool rated as meeting the fewest 
(9/35, 25.7%). Of the currently available tools, the Osteoporosis Choice tool rated the best overall 
(27/35, 77%). Only HealthDecision and the multimedia tool met the minimum criteria to be classified 
as a DA (see supplementary Table 2 for definition of classification criteria and Figure 4 for results). 
This was because the remainder DAs did not state the decision to be considered (AACE/ACE) or, 
more commonly, did not describe the physical, social and psychological consequences of the 
options, particularly of having a fracture. No DA met the certification criteria; most commonly this 
was because an update policy was not described or levels of uncertainty of the evidence were not 
described; however, 3/11 tools also did not describe benefits and harms of options in equal detail. 
Evidence that the DA was developed with review by patients or had been evaluated was only 
available for Osteoporosis Choice, the multimedia tool and the 2 DAs not currently available.  
Fig 4. Quality of decision aids evaluated using IPDAS criteria 
Public contributor views  
6 DAs were identified in the first environmental scan search (December 2017), and were presented 
to public contributors (with the Cochrane alendronate tool shown to represent all 3 Cochrane tools 
due to similar content). Six (female) public contributors attended the advisory discussion group. 
Public contributors found aspects of three tools confusing and difficult to understand 
(Supplementary Table 4). The NICE decision support tool was not well received and felt to cause 
confusion rather than to enhance understanding, because the example risk scenarios were not 
personalized and difficult to interpret. Parts of the text in the Cochrane tool and the layout of Cates 
plots in the HealthDecision tool were reported as confusing. The visualization of risk of rare harms 
(atypical fracture and osteonecrosis of the jaw) was welcomed in the HealthDecision tool; however, 
it was felt this image (a Cates plot of 1000 or 10,000 people) was too complicated to interpret easily. 
Osteoporosis Choice was the preferred DA to its appearance and relatively simple content, although 
it was felt this tool was missing visual information on harm risks. The group noted that information 
on harms of medication varied greatly between tools causing them to question the accuracy of this 
information. Additionally, the group felt that the tools seemed to downplay the significance of 
potential side effects (especially gastrointestinal).  
The public contributors felt their ideal DA would be computerized, web-based, suitable for use in a 
time-limited consultation, and include benefits and harms of drug treatment, both in written 
explanation and visual form. They suggested it would be helpful to have a print-out afterwards to 
study at their leisure and discuss with their general practitioner (GP). Public contributors stressed 
the need for a personalized risks as this meant they had more confidence in making an individualized 
and informed decision, based upon their own needs. They also felt the DA should give a brief 
overview of the information with an option for more in-depth evidence according to patient 
preference. Although Cates plot of 1000 people were felt to be too complicated, they liked the idea 
that rare harms could be presented alongside benefits in the same image and were positive about 
the suggestion to use alternative images for this, for example a football stadium infographic, which 
was felt to be an easily relatable image.  
  
Discussion 
We have conducted a comprehensive multifaceted review of the quality and effectiveness of DAs to 
support decision making about osteoporosis treatment, and gone beyond previous studies by 
embedding patient perspectives.  
We identified only six studies of clinical effectiveness, relating to four DAs, of which only two DAs 
are currently available. In the context of osteoporosis, we have found low quality evidence that 
decisional conflict reduces after the use of a DA, and that DA use increases SDM and increases 
patients’ accuracy of their perceived fracture risk. This finding is consistent with the Cochrane 
Systematic Review [9] which also found that DAs decrease decisional conflict, indecision about 
personal values, and the proportion of people who were passive in decision making. A subgroup 
analysis performed with the Cochrane review demonstrated use of DAs improved treatment 
initiation rates of preventative treatment to reduce risk of stroke in diabetes and hypertension. 
However, our review has not provided evidence that DAs improve treatment adherence in 
osteoporosis, although these results are limited by small numbers in the included studies and by 
different measures of treatment adherence across studies.  
It is important that further research on the effectiveness of DAs attends to both the decision quality 
(eg as measured by decisional conflict) and the decision process components of SDM [34]. In our 
study, two studies did not attend to this latter measure [19, 26]. Furthermore, as the ‘osteoporosis 
crisis’, characterized by poor treatment uptake, has been blamed on a failure of effective SDM, it is 
essential that further studies evaluating effectiveness of DAs evaluate the impact on adherence, and 
ideally using measures of both compliance and persistence. Moreover, the ability of osteoporosis 
DAs to address barriers to adherence, specifically low perceived need or high concerns, needs to be 
addressed. We have also identified that health literacy is an important consideration that needs to 
be evaluated in any further research.  
Our environmental scan identified 11 relevant DAs which varied from dynamic websites for use in 
the encounter to information leaflets with no interactive components that could be used pre- or 
post-consultation. Of 11 identified DAs, only the HealthDecision tool and the multimedia tool meet 
criteria to be classified as DA, but did not meet the full set of criteria for certification or quality. 
Across all the IPDAS criteria assessed, the Making Choices (Ottawa) and the Osteoporosis Choice DA 
performed best and also clearly report user involvement during development [19, 27, 28, 31] and it 
is therefore perhaps unsurprising that of the tools reviewed by the public contributors, the 
Osteoporosis Choice DA was viewed most favorably. Across the DAs, the IPDAS assessment 
identified that common deficiencies were found in describing the natural course of osteoporosis, 
helping patients imagine the consequences of options, including the physical, social and 
psychological consequences of sustaining a fracture, and using the same denominator in 
probabilities. Few DAs had information about their development or any evaluation and few 
described an update policy or reported any uncertainty around reported risks. The DAs included in 
this review varied in complexity and interactivity; the only included study in this review that 
measured health literacy reported greater gains with a simple booklet than with a multimedia tool 
and booklet combined [24]. 
The discussion group with patient contributors added to our evaluation using IPDAS. For example, 
although the Osteoporosis Choice DA was rated by authors as describing benefits and harms in equal 
detail, our patient contributors felt this DA lacked a visual displays of harms which would add value. 
Furthermore, although the HealthDecision DA was only one of two tools meeting criteria to be 
described as a DA, our public contributors found the visual presentations of risks too complicated to 
understand, highlighting the importance of user involvement in development, testing and 
evaluation. Our public contributors also reported that paper based tools that could be used before 
the consultation, that aimed to present a range of, or ‘average’ fracture risk(s), rather than 
personalized risk, were felt to be confusing.  Public contributors preferred tools which were web-
based and could offer information that could be individualized to their needs; this is in line with 
evidence, albeit of low certainty, that DAs with these characteristics are more effective at promoting 
adherence [35]. A recent systematic review of encounter DAs only concluded that these are effective 
in improving patient knowledge, reducing decisional conflict and did not increase the length of time 
of the consultation [36].  
Feedback from this discussion group informed a research proposal to design and evaluate a new DA 
to be used in the consultation when fracture prevention treatments are being considered. 
Subsequently, funding was secured to develop and evaluate a new DA, as part of a wider 
consultation intervention to improve informed decision-making regarding fracture prevention 
treatments (the iFraP study). A second public contribution group was convened in September 2018, 
in which plans for the co-production of the new DA were discussed, and the plans for public 
involvement in the overall research design in terms of needs assessment, user testing and 
design/refinement [13].  Public contributors expressed the importance of receiving consistent 
messages across primary and secondary care; thus, they advised that it was essential to involve 
primary care practitioners (GPs) as stakeholders in development of any new DA, despite the new DA 
being initially targeted specialist secondary care services. The group suggested that patients should 
provide informal feedback on early versions of the DA as part of iterative development. Members 
agreed to help interpret findings of ‘think aloud’ interviews used for more formal clinical testing of 
the prototype, in order to advise DA refinements ahead of a pilot study. Public contributors 
expressed preferences to have active roles in the study management and also felt they should be 
involved in the scientific advisory group, which would decide on the evidence which would underpin 
the DA. Integrating public contribution throughout these study groups was felt to facilitate patient 
input in all aspects of the study. Working together with public contributors to plan research at the 
outset is a key UK  Standard for Pubic Involvement [37]. However, a challenge remains to ensure we 
identify and address barriers to taking up public involvement in research, particularly in ensuring we 
involve a range of public with relevant experience and varied perspectives, particularly including 
those who have prominent concerns about medication. Continued recruitment of new members to 
our patient and public involvement group will be essential to provide a range of perspectives and 
avoid overburdening a small group of public contributors.   
A strength of this study is the use of multiple methods to bring together evidence about 
effectiveness and quality, and the views of public contributors to further our understanding. By 
supplementing the systematic review with an environmental scan and additional novel search 
methods, we were able to identify a comprehensive range of decision aids for quality assessment. 
However, this study is subject to a number of limitations. First, the real impact of DAs on SDM 
remains uncertain due to high or unclear risk of bias of all included studies. Lack of allocation 
concealment and blinding may have introduced significant bias favoring the intervention arm. 
However, decisional conflict was reduced consistently across trials and measured using the same 
validated scale, which decreases subjectivity and raises confidence in the results. We only sought 
feedback from public contributors about the DAs identified in the initial search, although of the 
currently available tools, the AACE/ACE, multimedia and Healthwise were excluded, none of which 
contain visualizations of risks, which the group preferred. The NICE DA was updated between the 
review by public contributors and the IPDAS assessment; however, the Cates plots were not altered 
meaning that the comments from the group relating to risk presentation and helpfulness are still 
relevant to the second version. A further limitation of this study relates to the fact that the IPDAS 
standards do not involve assessment of the quality of the evidence underpinning the DAs [12]; given 
the wide variation in frequencies of gastro-intestinal side effects reported, it is likely the tools were 
drawing on different sources of evidence. Furthermore, we did not directly assess readability of the 
DAs.  
Overall, our findings demonstrate that of the existing available tools, the Osteoporosis Choice tool 
best meets IPDAS criteria and has evidence of effectiveness, and, that paper based DAs which do not 
individualize risk should be used with caution, due to the confusion reported by our public 
contributors. However, the findings also underpin the need for a new DA that meets both IPDAS 
criteria and patient needs. Guidance on the development of DAs, derived from a systematic review 
and expert consensus, recommends five stages of development, overseen by a steering group from 
start to finish [38]. The stages involve i) scoping the need for the DA, ii) determining the design, by 
reviewing needs of patients and clinicians and reviewing the appropriate evidence, iii) designing a 
prototype, and iv) alpha and v) beta testing (usually in the field). Patients are recommended to be 
involved in the design, the testing phases and in the overseeing steering group. Our experience has 
demonstrated that reviewing existing tools has been an effective way of scoping the function of our 
proposed tool and a first step in determining patient decision needs. Further steps to determine 
patients’ needs will include qualitative research using focus groups, evidence synthesis of guidelines 
and patient information leaflets, and review of findings from a previous systematic review [39] and 
ongoing public collaboration throughout. A recent systematic review of user-involvement in DA 
development [13] has identified that more involvement of users in advisory and partnership roles is 
needed; our example demonstrates that public contributors are keen to be involved in advisory roles 
and have positively contributed to development of a new DA by advising on the format of DA 
printouts, and methods of informal alpha testing.  
At present, fracture prevention/osteoporosis DAs are not being widely used in routine practice. 
Furthermore, across a range of conditions, DA implementation in general is low with less than half of 
authors of trials included in the original Cochrane review reporting that the tested DA was being 
used in clinical practice [40]. Therefore, any new DA development needs to ensure barriers and 
facilitators to implementation in clinical practice are considered from the outset. The public 
contributor group were insightful here, suggesting early involvement of relevant stakeholders, 
including those from primary care, in development work, which we have already actioned.  
Conclusion 
In summary, by using a combined approach of a systematic review, environmental scan and 
consultation with public contributors, we have identified that existing osteoporosis decision aids 
show promise in increasing the accuracy of risk perception and shared decision-making, yet fail to 
comprehensively meet international quality standards and patient needs, suggesting a need for a 
new DA to address these deficits. Public contributors identified that DAs for osteoporosis need to be 
used in the consultation and individualized to their own needs and risk. We have briefly described 
planned public contribution in a new study to develop, design and evaluate a new DA.  
 
 
 
  
Declarations 
Funding: ZP is funded by the National Institute for Health Research (NIHR), Clinician Scientist Award 
(CS-2018-18-ST2-010)/NIHR Academy. AH is a NIHR funded Academic Clinical Fellow. CJ is part 
funded by the NIHR Applied Research Collaboration (ARC) West Midlands. The views expressed are 
those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the 
Department of Health and Social Care.  
Conflict of Interest: Juan P Brito, Victor D Torres Roldan, Meritxell Urtecho S, Nataly R. Espinoza 
Suarez, and Lisdamys Morera work at the Knowledge and Evaluation Unit at the Mayo Clinic where 
the Osteoporosis Choice tool was developed. Zoe Paskins, Ashley W Hawarden, Laurna Bullock, 
Gabriel F Torres, Anne Worrall, Steven Blackburn, Stephen Chapman, and Clare Jinks declare that 
they have no conflict of interest. 
Ethical approval: This article does not contain any studies with human participants or animals 
performed by any of the authors. 
Consent to participate: This article does not contain any studies with human participants or animals 
performed by any of the authors. 
Consent for publication: This article does not contain any studies with human participants or 
animals performed by any of the authors. 
  
1.  International Osteoporosis Foundation (2018) Broken Bones, Broken Lives: A roadmap to 
solve the fragility fracture crisis in the United Kingdom. http://share.iofbonehealth.org/EU-6-
Material/Reports/IOF_report_UK.pdf. Accessed 23 Dec 2019 
2.  van der Velde RY, Wyers CE, Teesselink E, Geusens PPMM, van den Bergh JPW, de Vries F, 
Cooper C, Harvey NC, van Staa TP (2017) Trends in oral anti-osteoporosis drug prescription in 
the United Kingdom between 1990 and 2012: Variation by age, sex, geographic location and 
ethnicity. Bone 94:50–55 . https://doi.org/10.1016/j.bone.2016.10.013 
3.  Hall SF, Edmonds SW, Lou Y, Cram P, Roblin DW, Saag KG, Wright NC, Jones MP, Wolinsky FD 
(2017) Patient-reported reasons for nonadherence to recommended osteoporosis 
pharmacotherapy. J Am Pharm Assoc 57:503–509 . 
https://doi.org/10.1016/j.japh.2017.05.003 
4.  Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and 
compliance with bisphosphonates for osteoporosis. Osteoporos. Int. 18:1023–1031 
5.  McHorney CA, Schousboe JT, Cline RR, Weiss TW (2007) The impact of osteoporosis 
medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. 
Curr Med Res Opin 23:3137–3152 
6.  Salter C, McDaid L, Bhattacharya D, Holland R, Marshall T, Howe A (2014) Abandoned Acid? 
Understanding adherence to bisphosphonate medications for the prevention of osteoporosis 
among older women: A qualitative longitudinal study. PLoS One 9:e83552 . 
https://doi.org/10.1371/journal.pone.0083552 
7.  Khosla S, Shane E (2016) A Crisis in the Treatment of Osteoporosis. J. Bone Miner. Res. 
31:1485–1487 
8.  Paskins Z, Jinks C, Mahmood W, Jayakumar P, Sangan CB, Belcher J, Gwilym S (2017) Public 
priorities for osteoporosis and fracture research: results from a general population survey. 
Arch Osteoporos 12:45 . https://doi.org/10.1007/s11657-017-0340-5 
9.  Stacey D, Légaré F, Lewis K, Barry MJ, Bennett CL, Eden KB, Holmes-Rovner M, Llewellyn-
Thomas H, Lyddiatt A, Thomson R, Trevena L (2017) Decision aids for people facing health 
treatment or screening decisions. Cochrane Database Syst Rev 12:CD001431 . 
https://doi.org/10.1002/14651858.CD001431.pub5 
10.  Elwyn G, Frosch D, Volandes AE, Edwards A, Montori VM (2010) Investing in deliberation: A 
definition and classification of decision support interventions for people facing difficult health 
decisions. Med Decis Mak 30:701–711 . https://doi.org/10.1177/0272989X10386231 
11.  National Institute for Health and Care Excellence (NICE). (2012) Patient experience in adult 
NHS services: improving the experience of care for people using adult NHS services. CG138. 
https://www.nice.org.uk/guidance/cg138. Accessed 23 Dec 2019 
12.  Joseph-Williams N, Newcombe R, Politi M, Durand MA, Sivell S, Stacey D, O’Connor A, Volk RJ, 
Edwards A, Bennett C, Pignone M, Thomson R, Elwyn G (2014) Toward minimum standards 
for certifying patient decision aids: A modified delphi consensus process. Med Decis Mak 
34:699–710 . https://doi.org/10.1177/0272989X13501721 
13.  Vaisson G, Provencher T, Dugas M, Trottier M-E, Chipenda-Dansokho S, Colquhoun H, 
Fagerlin A, Giguere A, Hakim H, Haslett L, Hoffman A, Ivers N, Julien A-S, Legare F, Renaud J-S, 
Stacey D, Volk R, Witteman H (2019) User involvement in the development of patient 
decision aids: A systematic review. https://doi.org/10.31219/OSF.IO/QYFKP 
14.  Torres-Roldan V, Urtecho LM, Espinoza N, Organick P, Thota A, Brito JP (2019) A systematic 
review and environmental scan of decision aids for osteoporosis: a review protocol. In: 
PROSPERO 2019 CRD42019126787. 
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42019126787. Accessed 
23 Dec 2019 
15.  Donnelly KZ, Thompson R (2015) Medical versus surgical methods of early abortion: Protocol 
for a systematic review and environmental scan of patient decision aids. BMJ Open 
5:e007966 . https://doi.org/10.1136/bmjopen-2015-007966 
16.  Graham P, Evitts T, Thomas-MacLean R (2008) Environmental scans: How useful are they for 
primary care research? Can. Fam. Physician 54:1022–1023 
17.  Doria N, Condran B, Boulos L, Curtis Maillet DG, Dowling L, Levy A (2018) Sharpening the 
focus: Differentiating between focus groups for patient engagement vs. qualitative research. 
Res. Involv. Engagem. 4:19 
18.  Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S, Altman DG, Moher D, 
Barber R, Denegri S, Entwistle A, Littlejohns P, Morris C, Suleman R, Thomas V, Tysall C (2017) 
GRIPP2 reporting checklists: Tools to improve reporting of patient and public involvement in 
research. BMJ 358:j3453 . https://doi.org/10.1136/bmj.j3453 
19.  Cranney A, O’Connor AM, Jacobsen MJ, Tugwell P, Adachi JD, Ooi DS, Waldegger L, Goldstein 
R, Wells GA (2002) Development and pilot testing of a decision aid for postmenopausal 
women with osteoporosis. Patient Educ Couns 47:245–255 . https://doi.org/10.1016/S0738-
3991(01)00218-X 
20.  Cranney A, Simon LS, Tugwell P, Adachi R, Guyatt G (2009) Postmenopausal Osteoporosis. In: 
Tugwell P, Shea B, Boers M, Brooks P, Simon L., Strand V, Wells G (eds) Evidence-Based 
Rheumatology. BMJ Books, pp 183–242 
21.  Watts NB, Manson JAE (2017) Osteoporosis and fracture risk evaluation and management: 
Shared decision making in clinical practice. J Am Med Assoc 317:253–254 . 
https://doi.org/10.1001/jama.2016.19087 
22.  Kunneman M, Branda ME, Hargraves I, Pieterse AH, Montori VM (2018) Fostering Choice 
Awareness for Shared Decision Making: A Secondary Analysis of Video-Recorded Clinical 
Encounters. Mayo Clin Proc Innov Qual Outcomes 2:60–68 . 
https://doi.org/10.1016/j.mayocpiqo.2017.12.002 
23.  Paskins Z, Worrall A, Chapman S (2018) Patient and public views of bisphosphonate decision 
aids: Not fit for purpose. In: Osteoporosis International. pp S374–S374 
24.  Lopez-Olivo MA, des Bordes JKA, Lin H, Rizvi T, Volk RJ, Suarez-Almazor ME (2019) 
Comparison of multimedia and printed patient education tools for patients with 
osteoporosis: a 6-month randomized controlled trial. Osteoporos Int. 
https://doi.org/10.1007/s00198-019-05210-4 
25.  Lopez-Olivo MA, Ingleshwar A, Volk RJ, Jibaja-Weiss M, Barbo A, Saag K, Leong A, Suarez-
Almazor ME (2018) Development and Pilot Testing of Multimedia Patient Education Tools for 
Patients With Knee Osteoarthritis, Osteoporosis, and Rheumatoid Arthritis. Arthritis Care Res 
70:213–220 . https://doi.org/10.1002/acr.23271 
26.  Oakley S, Walley T (2006) A pilot study assessing the effectiveness of a decision aid on patient 
adherence with oral bisphosphonate medication. Pharm J 276:536–538 
27.  Pencille LJ, Campbell ME, Van Houten HK, Shah ND, Mullan RJ, Swiglo BA, Breslin M, Kesman 
RL, Tulledge-Scheitel SM, Jaeger TM, Johnson RE, Bartel GA, Wermers RA, Melton LJ, Montori 
VM (2009) Protocol for the osteoporosis choice trial. A pilot randomized trial of a decision aid 
in primary care practice. Trials 10:113 . https://doi.org/10.1186/1745-6215-10-113 
28.  Montori VM, Shah ND, Pencille LJ, Branda ME, Van Houten HK, Swiglo BA, Kesman RL, 
Tulledge-Scheitel SM, Jaeger TM, Johnson RE, Bartel GA, Melton LJ, Wermers RA (2011) Use 
of a decision aid to improve treatment decisions in osteoporosis: The osteoporosis choice 
randomized trial. Am J Med 124:549–556 . https://doi.org/10.1016/j.amjmed.2011.01.013 
29.  Scoville EA, de Leon Lovaton PP, Shah ND, Pencille LJ, Montori VM (2011) Why do women 
reject bisphosphonates for osteoporosis? a videographic study. PLoS One 6:e18468 . 
https://doi.org/10.1371/journal.pone.0018468 
30.  Coylewright M, Branda M, Inselman JW, Shah N, Hess E, LeBlanc A, Montori VM, Ting HH 
(2014) Impact of sociodemographic patient characteristics on the efficacy of decision aids a 
patient-level meta-analysis of 7 randomized trials. Circ Cardiovasc Qual Outcomes 7:360–367 
. https://doi.org/10.1161/HCQ.0000000000000006 
31.  LeBlanc A, Wang AT, Wyatt K, Branda ME, Shah ND, Van Houten H, Pencille L, Wermers R, 
Montori VM (2015) Encounter decision aid vs. clinical decision support or usual care to 
support patient-centered treatment decisions in osteoporosis: The Osteoporosis Choice 
randomized trial II. PLoS One 10: . https://doi.org/10.1371/journal.pone.0128063 
32.  Hiligsmann M, Ronda G, van der Weijden T, Boonen A (2016) The development of a 
personalized patient education tool for decision making for postmenopausal women with 
osteoporosis. Osteoporos Int 27:2489–2496 . https://doi.org/10.1007/s00198-016-3555-1 
33.  Smallwood AJ, Schapira MM, Fedders M, Neuner JM (2017) A pilot randomized controlled 
trial of a decision aid with tailored fracture risk tool delivered via a patient portal. Osteoporos 
Int 28:567–576 . https://doi.org/10.1007/s00198-016-3767-4 
34.  Montori VM, Kunneman M, Brito JP (2017) Shared Decision Making and Improving Health 
Care The Answer Is Not In. JAMA August 15:617 . https://doi.org/10.1001/jama.2017.10289 
35.  Van de Velde S, Heselmans A, Delvaux N, Brandt L, Marco-Ruiz L, Spitaels D, Cloetens H, 
Kortteisto T, Roshanov P, Kunnamo I, Aertgeerts B, Vandvik PO, Flottorp S (2018) A 
systematic review of trials evaluating success factors of interventions with computerised 
clinical decision support. Implement. Sci. 13:114 
36.  Scalia P, Durand MA, Berkowitz JL, Ramesh NP, Faber MJ, Kremer JAM, Elwyn G (2019) The 
impact and utility of encounter patient decision aids: Systematic review, meta-analysis and 
narrative synthesis. Patient Educ. Couns. 102:817–841 
37.  Public Involvement Standards Development Partnership (2019) National Standards for Public 
Involvement in Research 
38.  Coulter A, Stilwell D, Kryworuchko J, Mullen PD, Ng CJ, Van Der Weijden T (2013) A 
systematic development process for patient decision aids. BMC Med Inform Decis Mak 13:S2 
. https://doi.org/10.1186/1472-6947-13-S2-S2 
39.  Raybould G, Babatunde O, Evans AL, Jordan JL, Paskins Z (2018) Expressed information needs 
of patients with osteoporosis and/or fragility fractures: a systematic review. Arch Osteoporos 
13:1–16 . https://doi.org/10.1007/s11657-018-0470-4 
40.  Stacey D, Suwalska V, Boland L, Lewis KB, Presseau J, Thomson R (2019) Are Patient Decision 
Aids Used in Clinical Practice after Rigorous Evaluation? A Survey of Trial Authors. Med Decis 
Mak 39:805–815 . https://doi.org/10.1177/0272989X19868193 
 
Inputs
To assess the efficacy of 
existing osteoporosis DAs
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To assess the quality of existing 
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To identify existing osteoporosis treatment DAs 
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• A systematic search of 7 
databases (March 2020)
Additional searches: 
• An existing DA database (Dec 
2017, Oct 2019, March 2020) 
• Social media (Oct 2019, March 
2020)
• Google (Oct 2019, March 2020)
Multifaceted understanding of the current state of evidence for osteoporosis treatment DAs; including efficacy, quality, 
and the extent that DAs meet patients’ needs.
Public contributor views
• DAs identified in the first DA database 
search (Dec 2017)
• Patient advisory group feedback
Systematic review
• A systematic search of 7 
databases (March 2020)
Fig 1. Overview of study methods
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To explore implications for further research
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Reasons for Exclusion (N): 
 Did not contain any 
tool (277) 
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SDM (51) 
 Other (72) 
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narrative summary 
N = 6 
*Reasons for exclusion are not mutually exclusive
Fig 3. Risk of bias of effectiveness studies
Fig 4. Quality of decision aids evaluated using IPDAS criteria
Items 1 2 3 4 5 6 7 8 9 10 11 n (%)
Describes condition ✓ ✓ ✓ ✓  ✓  ✓ ✓ ✓ ✓ 9 (81.8)
States the decision  ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 10 (90.9)
Describes options ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 11 (100)
Positive features ✓     ✓    ✓ ✓ 11 (100)
Negative features ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 11 (100)
Equal details ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 8 (72.7)
Natural course ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  ✓ ✓ 4 (36.4)
Fair comparison  ✓ ✓ ✓ ✓  ✓ ✓  ✓ 9 (81.8)
Outcome probabilities  ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 9 (81.8)
Reference class  ✓ ✓ ✓ ✓ ✓  ✓ ✓ ✓ 8 (72.7)
Event rates  ✓ ✓ ✓ ✓   ✓ ✓ ✓ 7 (63.6)
Same time period  ✓ ✓ ✓ ✓   ✓ ✓ ✓ 7 (63.6)
Same denominator  ✓ ✓ ✓ ✓   ✓   5 (45.5)
Viewing probabilities ✓ ✓ ✓ ✓ ✓   ✓ ✓ ✓ 8 (72.7)
Describes what it is like ✓     ✓     ✓ 3 (27.3)
What matter most  ✓ ✓ ✓  ✓ ✓ ✓   6 (54.5)
Step-by-step decision  ✓ ✓ ✓ ✓ ✓ ✓ ✓  ✓ 8 (72.7)
Worksheets  ✓ ✓ ✓  ✓  ✓   5 (45.5)
Patients' needs          ✓ 1 (9.1)
Professionals' needs          ✓ 1 (9.1)
Review by patients       ✓ ✓  ✓ ✓ 4 (36.4)
Review by professionals      ✓  ✓ ✓ ✓ 4 (36.4)
Tested with patients       ✓ ✓  ✓ ✓ 4 (36.4)
Tested with doctors       ✓ ✓  ✓ 3 (27.3)
Provides citations ✓ ✓ ✓ ✓ ✓ ✓  ✓ ✓ ✓ 9 (81.8)
Publication date  ✓ ✓ ✓ ✓ ✓  ✓ ✓ ✓ 8 (72.7)
Update policy     ✓    ✓  2 (18.2)
Levels of uncertainty  ✓ ✓ ✓   ✓    4 (36.4)
Evidence synthesis  ✓ ✓ ✓    ✓ ✓ ✓ 6 (54.5)
Quality of evidence  ✓ ✓ ✓    ✓   4 (36.4)
Funding source  ✓ ✓ ✓ ✓  ✓ ✓  ✓ ✓ 8 (72.7)
Credentials  ✓ ✓ ✓ ✓ ✓ ✓ ✓  ✓ ✓ 9 (81.8)
P
L Readibility evaluated           0 (0)
Better choices       ✓ ✓  ✓ ✓ 4 (36.4)
Improves knowledge       ✓ ✓  ✓ ✓ 4 (36.4)
IPDAS score, n (%) 9 (25.7) 23 (65.7) 23 (65.7) 23 (65.7) 18 (51.4) 17 (48.6) 17 (48.6) 28 (80.0) 15 (42.9) 27 (77.1) 14 (40.0)
1 AACE/ACE 2 Cochrane Alendronate 3 Cochrane Etidronate 4 Cochrane Risedronate  5 HealthDecision - Osteoporosis Shared Decision-Making tool 6 Healthwise -  Osteoporosis: Should I Take 
Bisphosphonate Medicines? 7 Healthy bones (AHRQ) 8 Making Choices: Osteoporosis Treatment Options (Cranney) 9 NICE 10 Osteoporosis Choice (Mayo Clinic) 11 Multi-media tool (Lopez 
Olivo)
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Table 1. Characteristics of included studies examining effectiveness of decision aids 
 
 
First author 
(year) 
Design Country Sample 
size 
Target population Sex Mean age Level of education Risk of fracture Decision Aid 
Tested 
Delivery Control 
Lopez-Olivo et 
al. (2019) 
Randomized 
Controlled 
Trial 
USA 225 Postmenopausal 
women with 
osteoporosis or 
osteopenia 
F Interventio
n: 63.1 
Control: 
64.7  
Intervention: Bachelor’s 
degree or higher: 31.5% 
Control: Bachelor’s 
degree or higher: 34.2% 
Not specified Multimedia 
patient 
education 
tool 
Not specified/self-
administered 
Written 
booklet 
Smallwood et 
al. (2016) 
Randomized 
Controlled 
Trial 
USA 50 Postmenopausal 
women with 
osteoporosis or 
osteopenia 
(treated or 
untreated) 
F Intervention: 
68.8 
Control: 67.8 
Intervention: High 
school, 10.3%; Post-
secondary, 89.7% 
 
Control: High school, 
19%; Post-secondary, 
80.9% 
Not specified Healthy 
Bones 
(modified) 
Before and within 
encounter/self-
administered 
Educational 
web-page 
LeBlanc et al. 
(2015) 
Randomized 
Controlled 
Trial 
USA 79 Postmenopausal 
women with 
untreated 
osteoporosis 
F Intervention: 
69 
Control: 66 
Intervention: High 
school or less, 25%; 
Post-secondary, 75% 
 
Control: High school or 
less, 24%; Post-
secondary 76% 
Intervention: <10% in 
10 years, 31%; >20% in 
10 years, 19%; FRAX 
mean, 14% 
Control: <10% in 10 
years, 47%;  >20%, 
15%; FRAX mean: 13% 
Osteoporosis 
Choice 
Within 
encounter/with 
clinician 
FRAX 
calculator/
Usual Care 
Montori et al. 
(2011) 
Randomized 
Controlled 
Trial 
USA 100 Postmenopausal 
women with 
untreated 
osteoporosis 
F Intervention: 
67 
Control: 67 
Intervention: Less than 
high school, 4%; High 
school or greater, 96% 
 
Control: Less than high 
school, 4%; High school 
or greater, 96% 
Intervention: <10% in 
10 years, 3.9%; >30%, 
19% 
Control: <10% in 10 
years, 8%; >30%, 31% 
Osteoporosis 
Choice 
Within 
encounter/with 
clinician 
Educational 
booklet 
Oakley et al. 
(2009) 
Randomized 
Controlled 
Trial 
Not 
specified 
33 Postmenopausal 
women with 
osteoporosis in 
treatment 
F Intervention: 
77 
Control: 77 
Not specified Intervention: previous 
fracture, n(%): 13(81) 
Control: previous 
fracture, n(%): 11(65) 
Ottawa 
decision aid 
(modified) 
Before 
encounter/self-
administered 
Usual care 
Cranney et al. 
(2002) 
Before and 
After Study 
Canada 20 Postmenopausal 
women with 
osteoporosis 
(treated or 
untreated) 
F 61.4 Less than high school, 
11%; Post-secondary, 
89% 
BMD (T score), -3.03 
(0.74) 
Making 
Choices 
(Ottawa 
decision aid) 
Before 
encounter/self-
administered 
Single arm 
Table 2. Effectiveness of decision aids 
Author (year) & Decision Aid tested 
Outcomes 
Lopez-Olivo et al. (2019) 
 
Multimedia patient education 
tool 
Smallwood et al. (2017) 
Healthy Bones (modified) 
LeBlanc et al. (2015) 
Osteoporosis Choice 
Montori et al. (2011) 
Osteoporosis Choice 
Oakley et al. (2006) 
Ottawa decision aid 
(modified) 
Cranney et al. (2002) 
Making Choices (Ottawa 
decision aid) 
Decisional Conflict 
They used a low literacy 
version of the Decisional 
Conflict scale.  
Decisional conflict decreased  
in both the multimedia (Post 
intervention: 16.0 (25.9), 3 
months: 33.7 (33.5), 6 months: 
27.9 (30.4) ).   
and printed booklet (Post 
intervention: 17.9 (28.2), 3 
months: 32.5 (32.8), 6 months: 
28.2 (32.1) )  groups (p < 0.05).  
 
They used the Decisional 
Conflict validated scale. 
Immediately post-intervention, 
there was a statistical 
significant lower decisional 
conflict in the decision aid arm 
(mean, 17.8) than controls 
(mean, 47.1). At 3 months: 
lower decisional conflict in the 
decision aid arm (mean, 11.2) 
compared to controls (mean, 
25.5). 
They used the Decisional 
Conflict validated scale. 
Immediately post intervention, 
not statistically significant 
difference between decision 
aid arm (median, 10.9; IQR, 25) 
and controls (median, 22.7; 
IQR, 20.7) 
They used the Decisional 
Conflict validated scale. 
Immediately post intervention, 
not statistically significant 
difference between decision 
aid arm (median, 10.9; IQR, 52) 
and controls (median, 13.3; 
IQR, 58) 
They used the Decisional 
Conflict validated scale. It was 
only assessed in the 
intervention group. 
Immediately post-intervention, 
they found a significant 
difference compared to 
baseline (median, 2.5; IQR, 1.6 
vs median, 2; IQR, 1.4; 
respectively). 
They used the Decisional 
Conflict validated scale (0-100). 
Immediately post-intervention, 
there was a statistical 
significant lower decisional 
conflict (mean, 37.4; SD, 14.2) 
than baseline (mean, 50.1; SD, 
15.9). 
Adherence N/A N/A 
Immediately post-intervention, 
they measured the % of 
patients that filled their 
prescription; they found that 
more patients in the decision 
aid arm (83%) filled their 
prescriptions when compared 
to controls (40%). At 6 months, 
they measured the % of days 
covered; they found no 
difference between 
intervention arm (median, 47; 
IQR, 7.5) and controls (median, 
85; IQR, 37.3). 
They measured the % of days 
covered. At 6 months, they 
found no difference between 
participants in the decision aid 
arm (median, 100; IQR, 14) and 
controls (median, 98; IQR, 
100). When they dichotomized 
at 80% days covered, they 
found a significant difference 
(100 vs 74, respectively) 
They used the Medication 
Adherence Report Scale 
(MARS) validated scale and 
reported % of "compliant" 
patients. At 4 months, there 
were no differences between 
the decision aid arm (median, 
100; IQR, 50) and controls 
(median, 100; IQR, 100). 
N/A 
Knowledge 
They used the modified version 
of the Osteoporosis Patient 
knowledge Questionnaire. 17-
item questionnaire. Knowledge 
improved from baseline to all 
evaluation time points in both 
the multimedia (Post 
intervention: 12.8 (3.2), 3 
months: 12.3 (3.1), 6 months: 
11.9 (3.1) )  and printed 
booklet groups (Post 
intervention: 12.4 (3.2), 3 
months: 11.9 (3.3), 6 months: 
11.8 (3.4) )   (p < 0.0001).  
 
N/A 
13-item questionnaire. 
Immediately post-intervention, 
they found a significant 
difference in knowledge 
specific to the decision aid -9 
questions- between the 
intervention arm (median, 6; 
IQR, 3) and controls (median, 
4; IQR, 3), but no difference in 
knowledge not specific to the 
DA -4 questions- (median, 1.5; 
IQR, 3; and median, 1.5; IQR, 3, 
respectively) 
13-item questionnaire. 
Immediately post-intervention, 
they found a significant 
difference in knowledge 
specific to the decision aid -9 
questions- between the 
intervention arm (median, 6; 
IQR, 9) and controls (median, 
4; IQR, 8), but no difference in 
knowledge not specific to the 
DA -4 questions- (median, 2; 
IQR, 4; and median, 1.5; IQR, 4, 
respectively) 
N/A 
27-item questionnaire and 
reported % of correct answers. 
Immediately post-intervention, 
they found a significant 
difference in overall knowledge 
(mean, 82; SD, 18.9) compared 
to baseline (mean, 46.7; SD, 
25.9). 
Realistic expectations N/A N/A 
They reported the % of 
patients who answered 
correctly their risk category. 
Immediately post-intervention, 
they found a significant 
difference in the proportion of 
patients that understood their 
risk without medication 
between the intervention arm 
(69%) and controls (35%). Also, 
more people understood their 
post-treatment risk reduction 
in the decision aid arm (79%) 
than the controls (30%). 
They reported the % of 
patients who answered 
correctly their risk category. 
Immediately post-intervention, 
they found a significant 
difference in the proportion of 
patients that understood their 
risk without medication 
between the intervention arm 
(49%) and controls (43%). Also, 
more people understood their 
post-treatment risk reduction 
in the decision aid arm (28%) 
than the controls (16%). 
N/A 
They used a 5-item 
questionnaire and reported % 
of correct answers. 
Immediately post-intervention, 
they found a significant 
difference in overall knowledge 
(mean, 56.3; SD, 26.6) 
compared to baseline (mean, 
17.5; SD, 16.7). 
Involvement in decision 
making 
N/A N/A 
They used the validated tool 
OPTION score. During the 
encounter, they found 
significantly higher 
involvement in the decision aid 
arm (mean, 57; SD, 3.5) than 
controls (mean, 43; SD, 3). 
They used the validated tool 
OPTION score. During the 
encounter, they found 
significantly higher 
involvement in the decision aid 
arm (median, 48; IQR, 81) than 
controls (median, 27; IQR, 73). 
N/A N/A 
Quality of life N/A N/A 
Measured at 6 months. They 
used the validated tool EURO 
QOL5d Health Thermometer. 
At 6 months, they did not 
observe any difference 
between the decision aid arm 
(median, 85; IQR, 15) and 
controls (median, 85; IQR, 17). 
N/A N/A N/A 
Preparation for SDM N/A 
They used the Preparation for 
Decision-Making validated 
scale. Immediately post-
intervention, they found a 
significant difference between 
subjects in the decision aid arm 
(mean, 68.1; SD, 23.4) and 
controls (mean, 39; SD, 29.4). 
N/A N/A N/A N/A 
Shared decision-making N/A 
They adapted 4 binary items 
from the DECISIONS study 
(assessed patient perceptions 
of any follow-up discussions 
with a primary care physician, 
including whether the subject 
was provided with alternative 
treatment options, discussed 
reasons for and against taking 
medication, and was asked 
what she wanted to do 
regarding treatment). At 3 
months, not statistically 
significant difference between 
those in the decision aid arm 
(mean, 3.19; SD, 1.2) compared 
to controls (mean, 2.9; SD, 
1.3). 
N/A N/A N/A N/A 
       
 
Supplementary Table 1. Search strategy 
Ovid 
Database(s): PsycINFO 1806 to January Week 4 2019, EBM Reviews - Cochrane Central 
Register of Controlled Trials December 2018, EBM Reviews - Cochrane Database of 
Systematic Reviews 2005 to January 30, 2019, Embase 1974 to 2019 February 04, Ovid 
MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily 
1946 to February 04, 2019  
Search Strategy: 
# Searches Results 
1 exp Osteoporosis/ 176948 
2 
("age-related bone loss*" or osteoporoses or osteoporosis or osteoporotic* or 
"pathologic decalcification*").ti,ab,hw,kw. 
244588 
3 1 or 2 244842 
4 *Decision Making, Computer-Assisted/ 10437 
5 *Decision Support Techniques/ 18858 
6 *Decision Support Systems, Clinical/ 5939 
7 *decision support system/ 12343 
8 *patient decision making/ 1996 
9 
(((decision* or decid*) adj2 (support* or aid* or tool* or instrument* or 
technolog* or technique* or system* or program* or algorithm* or process* or 
method* or intervention* or material*)) or (decision adj2 (board* or guide* or 
counseling)) or "adaptive conjoint analys*" or "decision making").ti,ab,hw,kw. 
775951 
10 4 or 5 or 6 or 7 or 8 or 9 775951 
11 3 and 10 2994 
12 limit 11 to english language [Limit not valid in CDSR; records were retained] 2793 
13 limit 12 to yr="2000 -Current" 2570 
14 remove duplicates from 13 2038 
 
 
Scopus 
1 TITLE-ABS-KEY("age-related bone loss*" or osteoporoses or osteoporosis or osteoporotic* or 
"pathologic decalcification*") 
2 TITLE-ABS-KEY(((decision* or decid*) W/2 (support* or aid* or tool* or instrument* or 
technolog* or technique* or system* or program* or algorithm* or process* or method* or 
intervention* or material*)) or (decision W/2 (board* or guide* or counseling)) or "adaptive 
conjoint analys*" or "decision making") 
3 PUBYEAR AFT 1999 AND LANGUAGE(english) 
4 1 and 2 and 3 
5 INDEX(embase) OR INDEX(medline) OR PMID(0* OR 1* OR 2* OR 3* OR 4* OR 5* OR 6* OR 7* 
OR 8* OR 9*) 
6 4 and not 5 
 
Web of Science 
 
1 TOPIC: (("age-related bone loss*" or osteoporoses or osteoporosis or osteoporotic* or 
"pathologic decalcification*")) AND TOPIC: ((((decision* or decid*) NEAR/2 (support* or 
aid* or tool* or instrument* or technolog* or technique* or system* or program* or 
algorithm* or process* or method* or intervention* or material*)) or (decision NEAR/2 
(board* or guide* or counseling)) or "adaptive conjoint analys*" or "decision making")) 
AND LANGUAGE: (English) Indexes=SCI-EXPANDED, ESCI Timespan=2000-2019 
2 PMID=(0* or 1* or 2* or 3* or 4* or 5* or 6* or 7* or 8* or 9*) 
3 1 NOT 2 
 
  
Supplementary Table 2. IPDAS criteria used   
Item Dimension Criteria Type of criteria 
(qualifying, certification 
or quality) 
Information The patient decision aid describes the health condition or 
problem (treatment, procedure, or investigation) for 
which the index decision is required. 
Qualifying 
 
The patient decision aid shows the negative and positive 
features of options with equal detail (e.g., using similar 
fonts, sequence, presentation of statistical information). 
Certification 
The patient decision aid describes the natural course of 
the health condition or problem, if no action is taken 
(when appropriate). 
Quality 
The patient decision aid explicitly states the decision that 
needs to be considered (index decision). 
Qualifying 
The patient decision aid makes it possible to 
compare the positive and negative features of 
the available options. 
Quality 
The patient decision aid describes the options available 
for the index decision.  
Qualifying 
The patient decision aid describes the positive 
features (benefits or advantages) of each option. 
Qualifying 
The patient decision aid describes the negative 
features (harms, side effects, or disadvantages) of 
each option. 
Qualifying 
Probabilities  The patient decision aid provides information about 
outcome probabilities associated with the options (i.e., 
the likely consequences of decisions). 
Quality 
The patient decision aid specifies the defined group 
(reference class) of patients for whom the outcome 
probabilities apply.  
Quality 
The patient decision aid specifies the event rates for the 
outcome probabilities. 
Quality 
The patient decision aid allows the user to compare 
outcome probabilities across options using the same time 
period (when feasible). 
Quality 
The patient decision aid allows the user to compare 
outcome probabilities across options using the same 
denominator. 
Quality 
The patient decision aid provides more than 1 way of 
viewing the probabilities (e.g., words, numbers, and 
diagrams).  
Quality 
Values The patient decision aid describes what it is like to 
experience the consequences of the options 
(e.g., physical, psychological, social). 
Qualifying 
The patient decision aid asks patients to think about 
which positive and negative features of the options 
matter most to them (implicitly or explicitly). 
Quality 
Guidance The patient decision aid provides a step-by-step way to 
make a decision. 
Quality 
The patient decision aid includes tools like worksheets or 
lists of questions to use when discussing options with a 
practitioner. 
Quality 
Development The development process included a needs assessment 
with clients or patients. 
Quality 
The development process included a needs assessment 
with health professionals. 
Quality 
The development process included review by 
clients/patients not involved in producing the decision 
support intervention.  
Quality 
The development process included review by 
professionals not involved in producing the 
decision support intervention. 
Quality 
The patient decision aid was field tested with patients 
who were facing the decision. 
Quality 
The patient decision aid was field tested with 
practitioners who counsel patients who face the decision. 
Quality 
Evidence The patient decision aid (or associated documentation) 
provides citations to the evidence selected. 
Certification 
The patient decision aid (or associated documentation) 
describes how research evidence was selected or 
synthesized. 
Quality 
The patient decision aid (or associated documentation) 
provides a production or publication date. 
Certification 
The patient decision aid (or associated documentation) 
describes the quality of the research evidence used. 
Quality 
The patient decision aid (or associated documentation) 
provides information about the update policy. 
Certification 
The patient decision aid provides information about 
the levels of uncertainty around event or outcome 
probabilities (e.g., by giving a range or by using phases 
such as ‘‘our best estimate is...’’). 
Certification 
Disclosure The patient decision aid (or associated documentation) 
provides information about the funding source used for 
development. 
Certification 
The patient decision aid includes authors’/developers’ 
credentials or qualifications. 
Quality 
Plain Language  The patient decision aid (or associated documentation) 
reports readability levels (using 1 or more of the available 
scales). 
Quality 
Evaluation There is evidence that the patient decision aid improves 
the match between the preferences of the informed 
patient and the option that is chosen. 
Quality  
There is evidence that the patient decision aid helps 
patients improve their knowledge about options’ 
features. 
Quality 
 
 
 
Supplementary Figure 1. Identification of DAs in environmental scan
 
  
Supplementary Table 3. Characteristics of included decision aids 
 Decision aid Availability and intended use Target populationPopulation Nature of options, and risks and 
benefits described 
Methods of displaying risks and benefits  
Multimedia patient education tool Freely available multimedia video and 
information leaflet. Video included: an 
overview of osteoporosis; description of 
the treatment options, including the 
harms/risks and benefits. Patient 
testimonials were included throughout.  
Evaluated for use in outpatients but 
designed to be read alone 
Post-menopausal women over 50 years 
old with a diagnosis of osteoporosis or 
osteopenia 
Risk of osteoporotic fracture with/ 
without treatment was not provided. 
Benefits and side effects of 
bisphosphonates (alendronate, 
ibandronate, risedronate, zoledronic 
acid), denosumab, hormones (estrogen, 
estrogen plus progestin, calcitonin, 
teriparatide), and raloxifene described. 
Effect of each drug on fracture risk 
reduction at ‘spine’ and ‘hip and other 
bones’ expressed by tick (evidence that 
the drug can prevent fracture) or 
question mark (unknown). 
Side effects described. 
 
Osteoporosis Choice (Mayo clinic). Freely available interactive (dynamic) 
website. Final results can be printed or 
emailed.  
Intended for use during the clinical 
encounter with a clinician. Details about 
fracture risk are entered. 
Adults aged 45-95 years. Risk of osteoporotic fracture with and 
without bisphosphonates and side 
effects of bisphosphonates.  
Two Cates plots (100 people “like you”) 
demonstrate fracture risk for those who 
take and those who do not take 
bisphosphonates. 
Side effects are textually presented using 
denominators of 4 and 10,000. 
HealthDecision Osteoporosis Shared 
Decision-Making Tool. 
Freely available interactive (dynamic) 
website. Final results can be copied and 
pasted into a word processor for 
printing. 
States best used by patients and 
clinicians together. Details about fracture 
risk are entered. 
Adults aged 40-90 years. Risk of osteoporotic fracture with and 
without bisphosphonates (alendronate, 
risdedronate, zoledronic acid) and side 
effects of bisphosphonates. 
A risk summary of major fracture and hip 
fracture is presented as a percentage 
over ten years. 
Cates plots (100, 1000 or 10000 people 
“like you”) demonstrate fracture risk for 
those who take and those who do not 
take bisphosphonates. Fracture risk is 
separated by type (hip or - wrist, upper 
arm and spine) within the same Cates 
plots. Side effects are presented within 
the same cates plots. 
Cochrane Musculoskeletal Decision Aids 
for alendronate (Fosfomax), etidronate 
(Didronel) and risedronate (Actonel). 
Freely available online as a PDF that can 
be downloaded and printed. 
States ‘a DA to discuss options with your 
doctor’. Includes sections to complete 
about values, decisions and knowledge. 
Post-menopausal women with a 
diagnosis of osteoporosis, osteopenia or 
low bone density that have sustained a 
recent fracture. 
Risk of osteoporotic fracture with and 
without bisphosphonates (alendronate, 
etidronate and risedronate) and side 
effects of bisphosphonates. 
Two Cates plots (100 women) showing 
‘best estimate’ hip fracture risk with a 
placebo drug and with a bisphosphonate. 
Two Cates plots (100 women) showing 
the number of people who stop 
treatment due to the side effects of 
bisphosphonate and with a placebo drug. 
Serious harms are presented textually 
using denominators of 10,000.  
A grading system is used to grade the 
accuracy of the estimates. 
Formatted Table
Formatted: Font: Not Bold
Formatted: Font: Not Bold
Formatted: Font: Not Bold
Formatted: Font: Not Bold
Formatted: Font: Not Bold
NICE bisphosphonate for treating 
osteoporosis patient decision aid. 
Freely available online as a PDF that can 
be downloaded and printed.  
States the DA will help clinicians explain 
the pros and cons. 
Women aged 65 and over, men aged 75 
and over, and other people who could be 
at higher risk of fractures.  
Risk of osteoporotic fracture with and 
without bisphosphonates and side 
effects of bisphosphonates. 
Three Cates plots (100 individuals) 
represent the risk of spinal fracture with 
and without bisphosphonates for a 
baseline fracture risk of 10, 20 and 30%. 
Three Cates plots (100 individuals) 
represent the risk of hip fracture with 
and without bisphosphonates for a 
baseline fracture risk of 10, 20 and 30%. 
Side effects are presented textually as 
“common”, “less common but serious”, 
“rare”, “very rare” and using a 
denominator of 100. 
Healthwise Osteoporosis: Should I Take 
Bisphosphonate Medicines? 
Freely available interactive (dynamic) 
website. Final results can be printed. 
States the ‘information will help you 
understand what your choices are so that 
you can talk to your doctor about them’. 
Includes sections to complete about 
values, decisions and knowledge. 
Post-menopausal women. Risk of osteoporotic fracture with and 
without bisphosphonates and side 
effects of bisphosphonates (mentions 
alendronate, risedronate, ibandronate 
and zoledronic acid). 
The DA indicates that the FRAX tool may 
be used to predict fracture risk and 
explains bisphosphonates lower fracture 
risk. 
Risk of rare side effects are presented 
using a denominator of 1000. No visual 
displays of fracture risk or harms 
AACE/ACE Osteoporosis Treatment 
Decision Tool. 
Freely available online as a PDF that can 
be downloaded and printed. Includes 
sections to complete about fracture risk 
No information about intended use. 
Not clearly specified. Risk of osteoporotic fracture described as 
low medium or high. Side effects and 
efficacy of bisphosphonates 
(alendronate, risedronate, ibandronate, 
zoledronic acid), denosumab, raloxifene, 
calcitonin, teriparatide, calcium, vitamin 
D and exercise described.  
Efficacy of drugs expressed using a “tick” 
based system. Five ticks represent 
maximum efficacy.  
The tool uses a bar chart to present an 
example of the 10-year fracture risk (with 
and without treatment) for an eighty-
year-old with a T score of -3.0, maternal 
history of hip fracture and a history of 
previous fracture.   
Extremely rare side effects are presented 
using denominators of 10,000 and 
100,000. 
Healthy Bones (AHRQ) No longer available. Originally designed 
to be embedded in patient record and 
used with clinician. Screenshot in 
associated paper used for quality 
assessment 
 Unknown Side effects and efficacy of 
bisphosphonates (alendronate, 
risedronate, ibandronate, zoledronic 
acid), denosumab, raloxifene and 
teriparatide described. 
Effect of each drug on fracture risk 
reduction at hip, back and other sites 
expressed by tick (some protection), 
cross (no protection) or unknown.  
Making Choices (Ottawa) No longer available. Originally paper 
based decision aid accompanied by 
patient booklet.  
Post-menopausal women with 
osteoporosis 
Risk of osteoporotic fracture with and 
without bisphosphonates (alendronate 
and etidronate), hormones and 
raloxifene. 
Three Cates plots (100 individuals) 
represent low, medium or high risk of 
spinal fracture at baseline. Text describes 
number of women with fewer broken 
hips if they are low/medium or high risk 
over a lifetime. Side effects described (no 
frequencies).  
 
  
Supplementary Table 4. Summary of public contributor discussion relating to each decision aid  
Decision aid Ease of Understanding Information about harms Helpfulness Implications for new 
DA/research  
Osteoporosis 
Choice (Mayo 
Clinic) 
Attractive layout 
Vertical layout of images in 
Cates plot preferred 
Seemed easy to understand 
Information (side effects) on 
abdominal problems not consistent 
with other resources 
Does not help prioritize values 
Does help understand 
treatment benefit 
Provides a useful model of 
displaying risk 
A new DA needs more 
information on treatment 
benefit 
HealthDecision 
Osteoporosis 
Shared Decision-
Making Tool  
The colors were not 
considered appealing 
Too much information on 
each plot 
Only tool to visualize risk of 
common side effects and rare 
harms 
Side effect information not 
believable about gastrointestinal 
side effects (too few) and not 
understandable as about placebo 
rather than drug itself 
Too complicated to make 
sense of 
The Cates plots of 10,000 
deemed the most potentially 
helpful (due to inclusion of rare 
harms) – but information too 
small to see 
Useful to visualize harms and 
benefits together, but 
alternative methods of 
displaying this need to be 
explored  
NICE 
bisphosphonate 
for treating 
osteoporosis 
patient decision 
aida 
Caused apprehension 
Implies the drugs don’t work 
Difficult to understand due to 
complicated terms and cates 
plots not interpretable 
Felt it was written for health 
professional rather than 
patient 
Text description of side effects clear Unclear how should be used  
Doesn’t help to understand 
purpose of drug 
Too complicated to make 
sense of 
Not practical for use in the 
consultation 
DAs need to demonstrate 
individual rather than 
‘average’ fracture risk 
Cochrane 
Decision Aid for 
alendronate  
Some language perceived as 
confusing – e.g. ‘by chance’, 
but generally simple language 
Cates plots for common side effects 
Compared side effects with placebo 
(although some found this 
confusing) 
Long, not suitable for 
consultation 
Section to check knowledge 
liked by some, while others 
found it patronizing 
Comparing outcomes in 
treatment vs placebo is 
confusing for some 
a Note NICE DA updated between public contributor discussion and IPDAS rating – comments relate to version 1 
 
